HBM Holdings (SEHK:2142) Valuation Check After FDA Green Light For HBM7004 Phase I Trial

Simply Wall St.

May 12

HBM Holdings (SEHK:2142) is drawing attention after U.S. regulators cleared its Investigational New Drug filing for HBM7004, allowing a first in human Phase I trial in advanced solid tumor patients. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2634259992"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634259992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634259992?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-12 06:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634259992","market":"sg","top_or_hot":-1,"title":"HBM Holdings (SEHK:2142) Valuation Check After FDA Green Light For HBM7004 Phase I Trial","media":"Simply Wall St.","content":"<div>\n<p>HBM Holdings (SEHK:2142) is drawing attention after U.S. regulators cleared its Investigational New Drug filing for HBM7004, allowing a first in human Phase I trial in advanced solid tumor patients. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-fda-green-light\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings (SEHK:2142) Valuation Check After FDA Green Light For HBM7004 Phase I Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings (SEHK:2142) Valuation Check After FDA Green Light For HBM7004 Phase I Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-12 06:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-fda-green-light><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HBM Holdings (SEHK:2142) is drawing attention after U.S. regulators cleared its Investigational New Drug filing for HBM7004, allowing a first in human Phase I trial in advanced solid tumor patients. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-fda-green-light\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-fda-green-light","article_id":"2634259992","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-fda-green-light","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634259992","pubTimestamp":1778538577,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"HBM Holdings (SEHK:2142) is drawing attention after U.S. regulators cleared its Investigational New Drug filing for HBM7004, allowing a first in human Phase I trial in advanced solid tumor patients.\nSee our latest analysis for HBM Holdings.\nThe FDA clearance appears to have arrived during a period of rebuilding momentum, with the share price at HK$13.5, a 90 day share price return of 15.29% and a 1 year total shareholder return of 64.63%. The 1 month share price return is down 5.26%.\nIf you...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1161":"生物科技","BK4168":"多种金属与采矿","BK4585":"ETF&股票定投概念","HBM":"HudBay Minerals Inc","LABU":"三倍做多标普生物-Direxion","02142":"和铂医药-B","BK1574":"生物医药B类股","DRAM":"Roundhill Memory ETF","BK1583":"高瓴概念"},"translate_title":"FDA批准HBM7004 I期试验后HBM Holdings(SEHK：2142)进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRAM":1.5,"LABU":1.5,"HBM":0.9,"02142":0.9,"DCF":1},"content_text":"HBM Holdings (SEHK:2142) is drawing attention after U.S. regulators cleared its Investigational New Drug filing for HBM7004, allowing a first in human Phase I trial in advanced solid tumor patients. See our latest analysis for HBM Holdings. The FDA clearance appears to have arrived during a period of rebuilding momentum, with the share price at HK$13.5, a 90 day share price return of 15.29% and a 1 year total shareholder return of 64.63%. The 1 month share price return is down 5.26%. If you are watching biotech catalysts like HBM7004 and want to see what else is moving, this is a good moment to scan 120 healthcare AI stocks With HBM Holdings trading at HK$13.50 and sitting well below the HK$19.99 analyst target, yet carrying a low value score and mixed earnings trends, should investors view this as potential upside or assume markets are already pricing in future growth? AdvertisementPreferred P/E of 15.8x: Is it justified? On a P/E of 15.8x and a last close of HK$13.50, HBM Holdings sits at a lower earnings multiple than many biotech peers, even though some models point to a richer valuation. The P/E multiple compares the share price to earnings per share and is a common yardstick for research focused biopharma stocks, where investors often weigh current profitability against the pipeline story. For HBM Holdings, that P/E sits alongside revenue of HK$157.98m, net income of HK$91.33m, a very large earnings growth rate over the past year, and a decline in annual net income growth of 4.91%. Compared with the Hong Kong Biotechs industry average P/E of 23x and the broader Asian Biotechs average of 37.5x, HBM Holdings trades on a markedly lower multiple. However, the estimated fair P/E of 14.3x from the SWS model implies the current 15.8x is modestly higher than the level that historical patterns suggest the market could gravitate toward, especially with earnings forecast to decline by an average of 4.9% a year over the next 3 years. Explore the SWS fair ratio for HBM Holdings Result: Preferred P/E of 15.8x (OVERVALUED) However, the recent decline in annual net income growth of 4.91% and the forecast that earnings may fall 4.9% a year could limit how much the P/E can expand. Find out about the key risks to this HBM Holdings narrative. Another View: DCF Points in the Opposite Direction While the P/E of 15.8x makes HBM Holdings look cheaper than many Hong Kong and Asian biotech peers, the SWS DCF model tells a different story. With the share price at HK$13.50 and the DCF value at HK$9.35, the stock screens as overvalued on future cash flows. For investors, that gap raises a simple question: is the current price reflecting earnings strength, or expectations that the cash generation profile might improve over time? Look into how the SWS DCF model arrives at its fair value. 2142 Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 227 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With sentiment pulled between potential rewards and clear risks, it makes sense to look at the full picture yourself and move quickly while the data is fresh, starting with 2 key rewards and 2 important warning signs Looking for more investment ideas? If HBM Holdings is on your radar, do not stop here. Use this moment to scan other focused ideas before the next move leaves you catching up.  Spot potential value by reviewing companies that screen as high quality yet possibly overlooked through the 227 high quality undervalued stocks. Strengthen your income focus by checking stocks that combine higher yields with resilience using the 484 dividend fortresses. Prioritise resilience by scanning companies with steadier risk profiles through the 305 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HBM Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}